GAITHERSBURG,
Md. and SHANGHAI, June 22,
2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company")
(Nasdaq: IMAB), a clinical-stage biopharmaceutical company
committed to the discovery, development, and commercialization of
pioneering immunotherapies, today announced the appointment of Mr.
Raj Kannan as the Company's new Chief Executive Officer and a
member of the board of directors effective June 22, 2023. This appointment serves as a
significant step towards further realizing I-Mab's mission of
delivering transformative therapies to patients worldwide.
Raj Kannan has over 30 years of industry experience in creating
and developing global specialty medicine franchises as a biotech
CEO. Mr. Kannan has successfully led blockbuster product launches
across several therapeutic areas including oncology both in the
U.S. and globally. More recently, as the Chief Executive Officer of
Aerie Pharmaceuticals, and before that of Chiasma Pharmaceuticals,
he delivered significant value to shareholders exiting both
companies successfully while increasing the potential reach of
approved and candidate medicines. Mr. Kannan's bio can be found
here.
"I am very pleased to welcome Mr. Raj Kannan on board. Raj joins
the Company at a critical juncture to strengthen its strategic
position as a U.S.-based global company. Raj is a distinguished
leader with the global experience and vision to drive sustainable
growth and realize the full potential of our differentiated
oncology portfolio as we move into our next phase of growth and
innovation," said Dr. Jingwu Zang,
Founder and Chairman of I-Mab. "I would also like to thank Dr.
Andrew Zhu, who had served as acting
Chief Executive Officer of the Company since September 2022. Andrew will continue to lead the
Company's R&D as President of I-Mab and serve as a member of
the board of directors."
"It is an exciting time to be joining I-Mab with the Company's
advanced and differentiated clinical assets generating promising
clinical data," said Mr. Kannan. "I look forward to working with
Dr. Zang and the talented team at I-Mab to further advance the
robust pipeline to deliver on the full potential of the portfolio
globally."
About I-Mab
I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company
focused on discovery, development and soon, commercialization of
novel or highly differentiated biologics in the therapeutic areas
of immuno-oncology and autoimmune diseases. The Company's mission
is to bring transformational medicines to patients around the world
through innovation. I-Mab's innovative pipeline of more than 10
clinical and pre-clinical stage drug candidates is driven by the
Company's Fast-to-Proof-of-Concept and Fast-to-Market development
strategies through internal R&D and global partnerships and
commercial partnerships. I-Mab has established its global footprint
in Shanghai, Beijing, Hangzhou, Lishui and Hong Kong in China, and Maryland and San
Diego in the United States. For more information,
please visit http://www.i-mabbiopharma.com and follow I-Mab on
LinkedIn, Twitter, and WeChat.
I-Mab Forward Looking Statements
This announcement contains forward-looking statements. These
statements are made under the "safe harbor" provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These
forward-looking statements can be identified by terminology such as
"will," "expects," "anticipates," "future," "intends," "plans,"
"believes," "estimates," "confident" and similar statements. I-Mab
may also make written or oral forward-looking statements in its
periodic reports to the U.S. Securities and Exchange Commission
(the "SEC"), in its annual report to shareholders, in press
releases and other written materials and oral statements made by
its officers, directors or employees to third parties. Statements
that are not historical facts, including statements about I-Mab's
beliefs and expectations, are forward-looking statements.
Forward-looking statements involve inherent risks and
uncertainties. A number of factors could cause actual results to
differ materially from those contained in any forward-looking
statement, including but not limited to the following: I-Mab's
ability to demonstrate the safety and efficacy of its drug
candidates; the clinical results for its drug candidates, which may
not support further development or NDA/BLA approval; the content
and timing of decisions made by the relevant regulatory authorities
regarding regulatory approval of I-Mab's drug candidates; I-Mab's
ability to achieve commercial success for its drug candidates, if
approved; I-Mab's ability to obtain and maintain protection of
intellectual property for its technology and drugs; I-Mab's limited
operating history and I-Mab's ability to obtain additional funding
for operations and to complete the development and
commercialization of its drug candidates; I-Mab's strategies,
plans, objectives and goals and I-Mab's ability to successfully
implement these strategies, plans, objectives and goals, as well as
those risks more fully discussed in the "Risk Factors" section in
I-Mab's most recent annual report on Form 20-F, as well as
discussions of potential risks, uncertainties, and other important
factors in I-Mab's subsequent filings with the SEC. All
forward-looking statements are based on information currently
available to I-Mab, and I-Mab undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events, or otherwise, except as
may be required by law.
I-Mab Contacts
Richard Yeh
|
Gigi Feng
|
Chief Operating
Officer, interim Chief Financial Officer
|
Chief Communications
Officer
|
IR@i-mabbiopharma.com
|
PR@i-mabbiopharma.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/i-mab-announces-the-appointment-of-raj-kannan-as-ceo-301857829.html
SOURCE I-Mab